Cresset Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Cresset Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$589K	Buy	15,742 +205	+1%	+$7.62K	﹤0.01%	1107
2026 Q1	$564K	Sell	15,537 -321	-2%	-$14.3K	﹤0.01%	1010
2025 Q4	$738K	Buy	15,858 +965	+6%	+$43K	﹤0.01%	913
2025 Q3	$620K	Hold	14,893	–	–	﹤0.01%	933
2025 Q2	$428K	Sell	14,893 -5	-0%	-$154	﹤0.01%	986
2025 Q1	$500K	Buy	14,898 +7,674	+106%	+$287K	﹤0.01%	1071
2024 Q4	$369K	Sell	7,224 -1,849	-20%	-$103K	﹤0.01%	1236
2024 Q3	$464K	Buy	9,073 +11	+0.1%	+$567	﹤0.01%	1562
2024 Q2	$406K	Buy	+9,062	New	+$418K	﹤0.01%	1549

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cresset Asset Management's CRNX Position: Q2 2026 in Review

Cresset Asset Management increased its Crinetics Pharmaceuticals (CRNX) stake by 1.3% in Q2 2026, buying an estimated $7.62K and bringing the position to 15,742 shares worth $589K. The position accounts for ﹤0.01% of the portfolio, ranked #1107.

Cresset Asset Management first reported a position in CRNX in Q2 2024 and has held it in 9 quarters since. The position peaked at $738K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Cresset Asset Management held 15,742 shares of Crinetics Pharmaceuticals worth $589K as of Q2 2026.
Cresset Asset Management bought 205 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $7.62K.
Crinetics Pharmaceuticals made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1107 holding.
Cresset Asset Management first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Cresset Asset Management's Crinetics Pharmaceuticals position peaked at $738K in Q4 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.